17 recruiting, 8 terminated, 7 active not recruiting, 6 completed. 25 Phase 2, 23 Phase 1, 3 Early Phase 1, 1 Not applicable.
Follow this condition Literature Review of Metastatic Triple-Negative Breast Carcinoma trials Research Report on Metastatic Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 20 | 2026-03-24 | 2026-08-04 |
| Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 30 | 2026-03-03 | 2026-04-24 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Radiation Therapy, Pembrolizumab, Nab-paclitaxel - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | Emory University | 29 | 2025-10-22 | 2026-04-17 |
| Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review - HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Recruiting | University of California, San Francisco | 100 | 2025-10-08 | 2026-10-16 | |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2025-02-01 | 2025-01-29 | |
| Neratinib in Combination With Ruxolitinib in Patients With mTNBC Neratinib Oral Tablet, Ruxolitinib Oral Tablet - Metastatic Triple-Negative Breast Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | Baylor Research Institute | 20 | 2024-09-16 | 2026-10-13 |
| Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 37 | 2024-09-01 | 2026-06-04 |
| Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment Cureety techcare - Metastatic Triple-Negative Breast Carcinoma | Not applicable | Terminated | UNICANCER | 31 | 2024-07-25 | 2026-09-29 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer Pembrolizumab, Cryoablation, Histotripsy - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2024-01-29 | 2026-09-14 |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Datopotamab Deruxtecan - Breast Cancer, Breast Cancer Female | Phase 2 | Recruiting | Nancy Lin, MD | 58 | 2024-01-08 | 2026-08-06 |
| Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer Ivermectin, Balstilmab, Pembrolizumab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Yuan Yuan | 34 | 2023-10-13 | 2026-08-05 |
| Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 160 | 2023-10-03 | 2026-06-24 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 32 | 2023-09-25 | 2026-07-31 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer 89Zr-atezolizumab PET/CT - Metastatic Triple-Negative Breast Carcinoma | Terminated | Karolinska University Hospital | 3 | 2023-07-01 | 2026-03-13 | |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2023-05-18 | 2026-09-30 |
Showing 20 of 47. Sign in to see all of them.
Triple Negative Breast Neoplasms (47) · Breast Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (7) · Lung Neoplasms (4) · Brain Neoplasms (3) · Carcinoma, Renal Cell (3) · Carcinoma, Transitional Cell (3) · Melanoma (3) · Carcinoma, Hepatocellular (2) · Hematologic Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Lobular (1)
Breast Diseases (47) · Neoplasms (47) · Neoplasms by Site (47) · Skin Diseases (47) · Skin and Connective Tissue Diseases (47) · Breast Neoplasms (35) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Neoplastic Processes (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7)
Biopsy (15) · pembrolizumab (15) · Magnetic Resonance Spectroscopy (13) · Specimen Handling (13) · Taxes (6) · 130-nm albumin-bound paclitaxel (4) · Albumin-Bound Paclitaxel (4) · Carboplatin (4) · Immunoglobulin G (4) · Paclitaxel (3) · X-Rays (3) · atezolizumab (3) · eribulin (3) · olaparib (3) · sacituzumab govitecan (3)
National Cancer Institute (NCI) (10) · Mayo Clinic (4) · Roswell Park Cancer Institute (4) · City of Hope Medical Center (3) · Emory University (3) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · Baylor Research Institute (1) · CytoDyn, Inc. (1) · Fundacio Clinic Barcelona (1) · Gilead Sciences (1) · Gordon Mills, MD, PhD (1) · Karolinska University Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Mridula George, MD (1)
United States (37) · Canada (1) · France (1) · Puerto Rico (1) · Singapore (1) · Spain (1) · Sweden (1)
Aleix Prat (1) · Ana C Garrido-Castro (1) · Brie Chun, MD (1) · David Maloney (1) · Elaine Lim, MD (1) · Ellis Levine, MD (1) · Emmanuel M Gabriel (1) · Eve T Rodler (1) · Evthokia Hobbs, M.D. (1) · Filipa Lynce (1) · Gordon Mills, MD, PhD (1) · Haiying Cheng (1) · Hussein A Tawbi, MD (1)
PMID 32379297, PMID 33357452, PMID 36623515, PMID 36873868, PMID 37023705, PMID 38028143, PMID 39038917, PMID 40933893, PMID 41611476, PMID 42847673
UM1CA186709 (4), P30CA138292 (2), UM1CA186689 (2), UM1CA186704 (2), K08CA279766 (1), P01CA234212 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), P50CA116201 (1), R01CA114536 (1), R01CA249116 (1), R44CA257278 (1), U10CA180888 (1)